A CAR T-cell therapy program for these diseases has been launched in Israel in 2024.
Contact us to check if CAR T-cell therapy is available for your condition.

Recent advancements in CAR T-cell therapy have shown promise in treating several autoimmune diseases, including lupus, rheumatoid arthritis, scleroderma, dermatomyositis, and vasculitis. Below are the latest developments for each:

Lupus

  • CAR T-cell therapy has been explored as a potential treatment for systemic lupus erythematosus (SLE). Studies have shown that targeting B cells with CAR T-cells can lead to significant improvements or even remissions in lupus patients. Clinical trials have demonstrated that a single infusion of CAR T-cells can eliminate or reduce symptoms and disease biomarkers, with some patients experiencing long-term remission without relapses.

Rheumatoid Arthritis

  • CAR T-cell therapy's ability to target and deplete autoreactive B cells could be beneficial in treating rheumatoid arthritis, similar to its application in other autoimmune conditions.

Scleroderma

  • CAR T-cell therapy has been tested in patients with systemic sclerosis (scleroderma) as part of broader studies on autoimmune diseases. Initial trials have shown potential in reducing symptoms and disease activity by targeting B cells.

Dermatomyositis

  • Dermatomyositis, a type of idiopathic inflammatory myopathy, has been included in studies exploring CAR T-cell therapy for autoimmune diseases. The therapy aims to achieve an immune reset by depleting autoreactive B cells, which could lead to symptom reduction and disease remission.

Vasculitis

  • The general approach of using CAR T-cells to target B cells in autoimmune diseases may offer potential benefits for vasculitis, given its autoimmune nature.